Publicaciones en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (31)

2023

  1. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis

    Cells, Vol. 12, Núm. 16

  2. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

  3. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. Comparative study of the lipid profile of tears and plasma enriched in growth factors

    Experimental Eye Research, Vol. 219

  2. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

    Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004

  3. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

  4. The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study

    European Respiratory Journal, Vol. 60, Núm. 3

2021

  1. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  2. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

  3. Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

    Hepatology, Vol. 73, Núm. 1, pp. 186-203

2020

  1. Multi‐omics integration highlights the role of ubiquitination in ccl4‐induced liver fibrosis

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-19

  2. Opipramol inhibits lipolysis in human adipocytes without altering glucose uptake and differently from antipsychotic and antidepressant drugs with adverse effects on body weight control

    Pharmaceuticals, Vol. 13, Núm. 3

2019

  1. Cholangiocarcinoma: State-of-the-art knowledge and challenges

    Liver International

  2. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

2018

  1. Dexamethasone protects retinal ganglion cells but not Müller glia against hyperglycemia in vitro

    PLoS ONE, Vol. 13, Núm. 11

  2. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1335-1344

  3. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

2017

  1. Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver

    Journal of Lipid Research, Vol. 58, Núm. 9, pp. 1903-1915

2016

  1. Glia-neuron interactions in the mammalian retina

    Progress in Retinal and Eye Research, Vol. 51, pp. 1-40

2015

  1. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)

    Journal of Controlled Release, Vol. 216, pp. 93-102